Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized single-blind multicenter trial of cyclosporine ophthalmic solution for dry eye disease
CTR20230285Phase 2Active
- Sponsor
- Essex Bio-Technology Limited
- Start
- Mar 2023
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of cyclosporine in dry eye syndrome (DED), sponsored by Essex Bio-Technology Limited. Started Mar 2023; status: active.
02
Drugs
cyclosporine
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on CTR20230285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230285.